Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Revenue (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Revenue for 7 consecutive years, with $321.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 210.77% to $321.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $958.4 million, a 432.05% increase, with the full-year FY2025 number at $958.4 million, up 432.05% from a year prior.
  • Revenue was $321.1 million for Q4 2025 at Madrigal Pharmaceuticals, up from $287.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $321.1 million in Q4 2025 to a low of $14.6 million in Q2 2024.